The 30+ year-old program, which monitors prenatal exposure to 164 drugs, should be the template for other efforts, US FDA officials say, because disease-based pregnancy registries ‘have a better track record.’

Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.

Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.

Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.